Breast Cancer

The ROW risk calculator makes its predictions based on age, comorbidities, functional status, tumor characteristics, and use of radiotherapy.

Quality of life in patients receiving netupitant/palonosetron chemotherapy induced nausea and vomiting.

Many breast cancer drugs approved in the United States may lack substantial clinical benefit, particularly in the palliative setting.

Researchers analyzed the association between baseline metabolic syndrome components and survival outcomes in women diagnosed with TNBC.

A review of the Pennsylvania Medical Marijuana Program defined the symptom profile of patients with breast cancer who sought to use medical marijuana.

More patients living with metastatic breast cancer reportedly would be willing to participate in clinical trials if some changes were made.

In the general population, BRCA1, BRCA2, PALB2, and ATM mutations were linked to a significant increased risk of breast cancer.

Estrogen alone and estrogen plus progestin appeared to have “opposite effects” on risk of breast cancer and death among postmenopausal women.